[Efficacy and safety of indacaterol - new long-acting beta(2) agonist].
Combination of ICS and LABA for asthmatics and several classes of long-acting bronchodilator drugs for COPD patients are recommended. Long-acting bronchodilator therapy should be always considered when patients are symptomatic. Incorporation of once daily dose administration is an important strategy to improve adherence and is the method preferred by most patients. Several trials evaluated the efficacy and safety of indacaterol in patients with asthma and COPD. The results of the study suggested that indacaterol has a wide therapeutic index and is safe and well tolerated.
Chazan
Ryszarda
R
Katedra i Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii WUM, ul. Banacha 1a, 02-097 Warszawa. rchazan@wum.edu.pl
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D009330:Nebulizers and Vaporizers; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D007189:Indans; D015363:Quinolones; C510790:indacaterol